Cilazapril is a new nonthiol group containing angiotensin converting enzyme (AGE) inhibitor, which was designed by a computer-modelling technique in order to obtain a compound with high specificity and selectivity for the target enzyme.
Cilazapril has been investigated in more than 4000 patients with all degrees of hypertension, as well as in special patient groups such as the elderly, renally impaired, and patients with concomitant diseases, such as congestive cardiac failure or chronic obstructive pulmonary disease. In these studies, the blood pressure-lowering effect of a single daily dose has been clearly established. The tolerability profile is similar to other frequently prescribed antihypertensive drugs, such as sustained-release propranolol, enalapril, captopril, atenolol and hydrochlorothiazide. Recently, investigations have revealed that cilazapril, in addition to its blood pressure-lowering abilities, can moderate the proliferative response seen in vessels after vascular injury caused by techniques such as ballooning. Clinical studies to verify these findings are currently ongoing.
KeywordsAngiotensin Converting Enzyme Atenolol Angiotensin Converting Enzyme Inhibitor Hydrochlorothiazide HCTZ
Unable to display preview. Download preview PDF.
- Dzau VJ. Autocrine-paracrine renin-angiotensin systems in cardiorenal regulation and the pharmacology of ACE inhibitors. In Sonneblick EH, Laragh JH, Lesch M (Eds) New frontiers in cardiovascular therapy: focus on angiotensin converting enzyme inhibition, pp. 13–28, Excerpta Medica, Princeton, 1989Google Scholar
- Francis RJ, Brown AN, Kler L, Fasanella d’Amore T, Nussberger J, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. Journal of Cardiovascular Pharmacology 9: 32–38, 1987PubMedGoogle Scholar
- Laragh JH. The renin system and the impact of ACE inhibition for understanding, diagnosis, and treatment of hypertension. In Sonnenblick EH, Laragh JH, Lesch M (Eds) New frontiers in cardiovascular therapy: focus on angiotensin converting enzyme inhibition, pp. 83–116, Excerpta Medica, Princeton, 1989Google Scholar
- Sanchez RA, Traballi CA, Barclay CA, Gilbert HB, Muscará M, et al. Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension. Journal of Cardiovascular Pharmacology 11: 230–234, 1988PubMedGoogle Scholar
- Sealey JE. A separate prorenin-angiotensin system in reproductive and renal tissues? Evidence for renin gene expression in extrarenal vascular tissues is unconvincing. In Sonnenblick EH, Laragh JH, Lesch M (Eds) New frontiers in cardiovascular therapy: focus on angiotensin converting enzyme inhibition, pp. 29–46, Excerpta Medica, Princeton, 1989Google Scholar